Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.64 |
| ▸ | CDK4 | P11802 | 15/20 | 0.64 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 5/20 | 0.52 |
| ▸ | CDK1 | P06493 | 5/20 | 0.52 |
| ▸ | CDK7 | P50613 | 5/20 | 0.52 |
| ▸ | CDK9 | P50750 | 5/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684382 | 0.92 | CDK2 (0.60) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL2075981 | 0.90 | CDK2 (0.66) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL4162202 | 0.89 | CDK2 (0.61) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL2086669 | 0.86 | CDK2 (0.55) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL1806918 | 0.83 | CDK2 (0.74) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL4161727 | 0.82 | CDK2 (0.63) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL4169340 | 0.81 | CDK2 (0.74) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL4160096 | 0.81 | CDK2 (0.70) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL2073966 | 0.80 | CDK2 (0.68) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL2284091 | 0.79 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | CDK2 1/4885CDK4 2/4885PLK1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.